Pancreatic Cancer Research

ResearcherHarbin Medical UniversityNo recent work listed

Le Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4999-2288; OpenAlex author ID A5100450293. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 8

  1. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … First author DOI 10.1002/advs.202203324↗
  2. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  3. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  4. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00612↗
  5. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  6. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. First author DOI 10.1007/s10637-017-0508-2↗
  7. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41419-018-0839-8↗
  8. Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy. Co-author DOI 10.1158/1535-7163.mct-16-0008↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jisheng Hu · 6 shared papers, 2018–2023 · strength 0.67
  2. Rui Kong · 7 shared papers, 2016–2023 · strength 0.67
  3. Yongwei Wang · 6 shared papers, 2016–2023 · strength 0.58
  4. Hongze Chen · 5 shared papers, 2018–2023 · strength 0.57
  5. Bei Sun · 6 shared papers, 2016–2022 · strength 0.53
  6. Zhongjie Zhao · 4 shared papers, 2019–2023 · strength 0.49
  7. Yilong Li · 5 shared papers, 2018–2022 · strength 0.47
  8. Shangha Pan · 4 shared papers, 2018–2023 · strength 0.44
  9. Chundong Cheng · 3 shared papers, 2022–2023 · strength 0.41
  10. Danxi Liu · 3 shared papers, 2022–2023 · strength 0.41
  11. Guanqun Li · 3 shared papers, 2018–2023 · strength 0.36
  12. Xinglong Geng · 2 shared papers, 2023 · strength 0.28
  13. Wenbo Yang · 2 shared papers, 2023 · strength 0.28
  14. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  15. Bei Sun · 2 shared papers, 2023 · strength 0.28
  16. Gang Wang · 3 shared papers, 2016–2023 · strength 0.28
  17. Tao Zhang · 2 shared papers, 2022–2023 · strength 0.27
  18. Xuewei Bai · 2 shared papers, 2016–2023 · strength 0.19
  19. Zengfu Song · 1 shared paper, 2023 · strength 0.14
  20. Yan Luo · 1 shared paper, 2023 · strength 0.14
  21. Yongwei Wang · 1 shared paper, 2022 · strength 0.13
  22. Gang Wang · 1 shared paper, 2022 · strength 0.13
  23. Zonglin Liu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.